Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,264 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pathways Clear all
Completed No phase listed Observational

Study of Heart Transplant Rejection

NCT00042614
View directory record Official record
Conditions
Heart Transplantation
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 3:12 AM EDT
Terminated Phase 2 Interventional Results available

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

NCT01120275
View directory record Official record
Conditions
Acral Lentiginous Malignant Melanoma, Lentigo Maligna Malignant Melanoma, Nodular Malignant Melanoma, Recurrent Melanoma, Solar Radiation-related Skin Melanoma, Stage IV Melanoma, Superficial Spreading Malignant Melanoma
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
178
States / cities
Mobile, Alabama • Fairbanks, Alaska • Tucson, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 18, 2026, 3:12 AM EDT
Withdrawn Phase 1 Interventional

Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer

NCT02581501
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
GAX - Gemcitabine, Abraxane and Xeloda
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 18, 2026, 3:12 AM EDT
Terminated Phase 2 Interventional Results available

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

NCT01122901
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
5
States / cities
Atlanta, Georgia • Detroit, Michigan • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 18, 2026, 3:12 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

NCT02047253
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Carfilzomib, Dexamethasone, Acyclovir
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Macon, Georgia • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 18, 2026, 3:12 AM EDT
Recruiting No phase listed Observational

PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification

NCT05049837
View directory record Official record
Conditions
Lung Cancer, Cancer of Thorax
Interventions
Group Specific Aim 1, Group Specific Aim 2, Group Specific Aim 3, Group Specific Aim 4, Group Specific Aim 5, Group Specific Aim 6
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 18, 2026, 3:12 AM EDT
Available No phase listed Expanded access

Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

NCT06963697
View directory record Official record
Conditions
Cancer
Interventions
Personalized Synthetic Long Peptide Vaccine
Biological
Lead sponsor
Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Other
Eligibility
12 Years and older
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 18, 2026, 3:12 AM EDT
Completed Not applicable Interventional

Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial

NCT04872413
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Biospecimen Collection, Follow-Up
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 18, 2026, 3:12 AM EDT
Recruiting Not applicable Interventional

Retraining Neural Pathways Improves Cognitive Skills After A Mild Traumatic Brain Injury

NCT03655782
View directory record Official record
Conditions
MTBI - Mild Traumatic Brain Injury
Interventions
PATH + DigitMemory (DM) neurotraining
Behavioral
Lead sponsor
Perception Dynamics Institute
Industry
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
San Diego, California • Solana Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 3:12 AM EDT
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 18, 2026, 3:12 AM EDT
Not yet recruiting Phase 2 Interventional

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT07645326
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation, Docetaxel
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 3:12 AM EDT
Completed Phase 1 Interventional

Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)

NCT02086526
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 18, 2026, 3:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the Heart

NCT00447629
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
PPM-204
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 18, 2026, 3:12 AM EDT
Completed Phase 2 Interventional Results available

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

NCT04963231
View directory record Official record
Conditions
Genetic Obesity
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Scottsdale, Arizona • Suwanee, Georgia • Worcester, Massachusetts + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 18, 2026, 3:12 AM EDT
Not listed Not applicable Interventional

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

NCT02015728
View directory record Official record
Conditions
Recurrent Childhood Brain Tumor
Interventions
Tumor biology testing, Temozolomide, Etoposide, Sorafenib, Everolimus, Erlotinib, Dasatinib
Device · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 18, 2026, 3:12 AM EDT
Not yet recruiting Phase 1 Interventional

LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults

NCT07463365
View directory record Official record
Conditions
Venous Leg Ulcer, Chronic Non-Healing Cutaneous Wounds, VLU
Interventions
LUT017 gel
Drug
Lead sponsor
Antoni Ribas
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 18, 2026, 3:12 AM EDT
Active, not recruiting No phase listed Observational

Left Atrial Pressure-Guided Heart Failure Optimization During Atrial Fibrillation Ablation (LAP AF-HF)

NCT07594886
View directory record Official record
Conditions
Atrial Fibrillation (AF), Heart Failure, Catheter Ablation, Guideline Implementation
Interventions
LAP-Triggered Heart Failure Optimization Pathway
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 18, 2026, 3:12 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Mechanism of Weight Loss After Endoscopic and Laparoscopic Sleeve Procedures

NCT04006002
View directory record Official record
Conditions
Weight Loss, Reflux
Interventions
Metabolic and Hormonal profile
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 18, 2026, 3:12 AM EDT
Completed Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Children With Visual Pathway Glioma

NCT00003477
View directory record Official record
Conditions
Visual Pathway Glioma
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
6 Months to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 18, 2026, 3:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pathways Linking Reduced Sleep Duration and Quality to Obesity Risk

NCT00915707
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
Baseline, Sleep restriction, Reduced Sleep Quality
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 18, 2026, 3:12 AM EDT
Terminated No phase listed Observational

Wnt, Notch and Hedgehog Activity in Chemo-Naive Tumors Collected During Staging of Esophageal Cancer Patients

NCT02221245
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Tumor Biopsy via Ultrasound Endoscopy
Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 18, 2026, 3:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial of Tadalafil and Glycemic Traits

NCT01444651
View directory record Official record
Conditions
Cardiovascular Disease, Insulin Resistance, Glucose Intolerance, Obesity
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Thomas J. Wang, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 18, 2026, 3:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quadratus Lumborum Versus Transversus Abdominis Plane Nerve Block: A Comparison Study

NCT03490357
View directory record Official record
Conditions
Anesthesia
Interventions
Control - Transversus Abdominus Plane Block, Quadratus Lumborum Block
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 18, 2026, 3:12 AM EDT
Withdrawn Not applicable Interventional

Pathways to Improving Functional Capacity in Older Patients With Chronic Kidney Disease and Cardiovascular Disease

NCT02473705
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Fish Oil and Bicarbonate, Fish Oil and Bicarbonate Placebo, Fish Oil Placebo and Bicarbonate, Fish Oil Placebo and Bicarbonate Placebo
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 18, 2026, 3:12 AM EDT